

Confidential. Do not distribute. Pre-embargo material.

Original Investigation

Association Between Hospitalization With Community-Acquired Laboratory-Confirmed Influenza Pneumonia and Prior Receipt of Influenza Vaccination

Carlos G. Grijalva, MD, MPH; Yuwei Zhu, MD, MS; Derek J. Williams, MD, MPH; Wesley H. Self, MD, MPH; Krow Ampofo, MD; Andrew T. Pavia, MD; Chris R. Stockmann, MSc; Jonathan McCullers, MD; Sandra R. Arnold, MD; Richard G. Wunderink, MD; Evan J. Anderson, MD; Stephen Lindstrom, PhD; Alicia M. Fry, MD, MPH; Ivo M. Foppa, ScD, MD; Lyn Finelli, DrPH, MS; Anna M. Bramley, MPH; Seema Jain, MD; Marie R. Griffin, MD, MPH; Kathryn M. Edwards, MD

IMPORTANCE Few studies have evaluated the relationship between influenza vaccination and pneumonia, a serious complication of influenza infection.

OBJECTIVE To assess the association between influenza vaccination status and hospitalization for community-acquired laboratory-confirmed influenza pneumonia.


DESIGN, SETTING, AND PARTICIPANTS The Etiology of Pneumonia in the Community (EPIC) study was a prospective observational multicenter study of hospitalizations for community-acquired pneumonia conducted from January 2010 through June 2012 at 4 US sites. In this case-control study, we used EPIC data from patients 6 months or older with laboratory-confirmed influenza infection and verified vaccination status during the influenza seasons and excluded patients with recent hospitalization, from chronic care residential facilities, and with severe immunosuppression. Logistic regression was used to calculate odds ratios, comparing the odds of vaccination between influenza-positive (case) and influenza-negative (control) patients with pneumonia, controlling for demographics, comorbidities, season, study site, and timing of disease onset. Vaccine effectiveness was estimated as $(1 - \text{adjusted odds ratio}) \times 100\%$.


EXPOSURE Influenza vaccination, verified through record review.

MAIN OUTCOMES AND MEASURES Influenza pneumonia, confirmed by real-time reverse-transcription polymerase chain reaction performed on nasal/oropharyngeal swabs.

RESULTS Overall, 2767 patients hospitalized for pneumonia were eligible for the study; 162 (5.9%) had laboratory-confirmed influenza. Twenty-eight of 162 cases (17%) with influenza-associated pneumonia and 766 of 2605 controls (29%) with influenza-negative pneumonia had been vaccinated. The adjusted odds ratio of prior influenza vaccination between cases and controls was 0.43 (95% CI, 0.28-0.68; estimated vaccine effectiveness, 56.7%; 95% CI, 31.9%-72.5%).

CONCLUSIONS AND RELEVANCE Among children and adults hospitalized with community-acquired pneumonia, those with laboratory-confirmed influenza-associated pneumonia, compared with those with pneumonia not associated with influenza, had lower odds of having received influenza vaccination.

 Author Video Interview and JAMA Report Video at jama.com

 Supplemental content at jama.com

Author Affiliations: Author affiliations are listed at the end of this article.

Corresponding Author: Carlos G. Grijalva, MD, MPH, Department of Health Policy, Vanderbilt University School of Medicine, 1500 21st Ave S, The Village at Vanderbilt Ste 2600, Nashville, TN 37212 (carlos.grijalva@vanderbilt.edu).

Confidential. Do not distribute. Pre-embargo material.

Influenza remains an important cause of morbidity and mortality worldwide. In the United States, seasonal influenza epidemics are responsible for an estimated average of 226 000 hospitalizations and between 3000 and 49 000 deaths each year.^{1,2} Pneumonia, the leading infectious cause of hospitalization and death in the United States, is a relatively common and serious complication of influenza.³

Vaccination is the primary strategy to reduce influenza burden. Currently, the US Advisory Committee on Immunization Practices (ACIP) recommends annual influenza vaccination for all persons 6 months or older.^{1,2} Supporting evidence from randomized clinical trials, conducted mainly in outpatient settings, indicates that influenza vaccines are effective in preventing influenza-associated acute respiratory illnesses among healthy children and adults.^{4,5}

Vaccine effectiveness studies based on laboratory-confirmed influenza infections and verified vaccinations are essential to evaluate the public health value of influenza vaccines and to inform vaccination policies.^{6,7} Recent observational studies have consistently shown that vaccination is associated with lower odds of hospitalization for laboratory-confirmed influenza acute respiratory infections.^{3,7-14}

However, whether influenza vaccines can decrease the risk of influenza-associated hospitalizations for community-acquired pneumonia remains unclear.^{5,6,15} Because influenza vaccination is currently recommended for all persons 6 months or older in the United States, observational studies are the only option to assess vaccine effectiveness. We sought to determine whether influenza vaccination was associated with reduced odds of hospitalizations for laboratory-confirmed influenza-associated pneumonia.

Methods

The US Centers for Disease Control and Prevention (CDC) Etiology of Pneumonia in the Community (EPIC) Study was conducted from January 2010 through June 2012.^{16,17} Children and adults admitted with community-acquired pneumonia were enrolled at 8 hospitals in 4 sites: Nashville, Tennessee; Memphis, Tennessee; Chicago, Illinois; and Salt Lake City, Utah. Pneumonia was defined as evidence of acute infection, symptoms of respiratory illness, and radiologic findings compatible with pneumonia. Patients with history of recent hospitalization, children who were residents of chronic care facilities, adults who were nursing home residents and not independently functioning (defined as score >7 in the Activities of Daily Living scale¹⁷), and patients with severe immunosuppression were excluded.^{16,17} Written informed consent was obtained from all participants, their legally authorized representatives, or both. After enrollment, research personnel collected sociodemographic characteristics (including interview self-reported race/ethnicity), pneumonia risk factors, and health care utilization information, including vaccination history. Because children younger than 6 months are not eligible for influenza vaccination, the study was restricted to patients 6 months or older. Institutional review boards of the research sites and CDC approved the study.^{16,17}

Laboratory Confirmation of Influenza Virus Infections

Nasopharyngeal and oropharyngeal swabs were collected from each patient at enrollment, placed into transport medium, and delivered to the site research laboratories. Samples were stored at -70°C and then tested in batches for influenza and other respiratory viruses using CDC's real-time reverse-transcription polymerase chain reaction (RT-PCR) protocols.^{16,17} To ensure integrity of the samples, the presence of human RNaseP, a housekeeping gene, was required for evaluable samples. Laboratory personnel conducting the RT-PCR testing were blinded to the patients' vaccination status and study hypotheses.

Cases and Controls

For this case-control study, a case was a patient hospitalized for pneumonia whose nasopharyngeal/oropharyngeal swabs collected within 72 hours of admission tested positive for influenza by RT-PCR with a cycle threshold value of less than 40. A control was a patient hospitalized for pneumonia who tested negative for influenza.^{3,7-14,18} Only patients with verified influenza infection status were included in the study.^{19,20}

Influenza Vaccination Status

The study exposure was verified influenza vaccination status for the current influenza season. Detailed influenza vaccination history was collected in the study interview, and medical records were reviewed for verification. We also obtained vaccination information from state vaccination registries and from health care providers and pharmacies. Vaccination status included receipt of monovalent vaccines (2009-2010 season) or trivalent inactivated or live attenuated influenza vaccines (2010-2011 and 2011-2012 seasons). Per ACIP recommendations, children younger than 9 years were considered vaccinated if they had received (1) 2 vaccine doses for the current influenza season, with a time between doses of 28 days or longer and the second dose more than 14 days before their disease onset, or (2) 1 or more vaccine doses in the prior influenza seasons and 1 dose for the current season more than 14 days before their disease onset. Children 9 years and older and adults were considered vaccinated if they had received any influenza vaccine for the current season more than 14 days before their disease onset.^{1,2} Partially vaccinated children and patients of any age whose influenza vaccination history could not be verified were excluded.

Influenza Seasons

To ensure a proper evaluation of the association between influenza pneumonia risk and prior influenza vaccination, we restricted our analyses to periods of influenza activity at each site, based on CDC surveillance data.²¹ We defined the beginning of the influenza season as the first week of continuous influenza activity with 2 or more positive tests for influenza virus identified in each of 2 consecutive weeks by the respective regional surveillance system. The season ended on the last of 2 consecutive weeks with less than 2 positive tests detected per week.²² Study enrollment was conducted from January 2010 through June 2012 and thus included part of the 2009-2010 season and the complete 2010-2011 and 2011-2012

Confidential. Do not distribute. Pre-embargo material.

influenza seasons. (See eTable 1 and the eFigure in the Supplement for additional details.)

Statistical Analyses

We examined associations between potential confounders (identified a priori) and verified vaccination status as well as laboratory-confirmed influenza pneumonia. Potential confounders included age, sex, race/ethnicity, family composition (eg, presence of young or school-aged children), smoking status, insurance status, use of oxygen supplementation at home, timing of admission relative to disease onset, timing from beginning of the influenza season to admission (because disease risk may vary during the seasons), specific influenza season, and presence of immunosuppressive conditions (including also cancer [except skin cancer] and HIV infection [with CD4 counts $\geq 200/\text{mm}^3$]) and other chronic medical conditions associated with influenza-associated complications, including cardiopulmonary disease, diabetes mellitus, chronic liver/kidney disease, and neurological disease.^{1-3,8}

We compared the odds of influenza vaccination during the current season more than 14 days before disease onset between influenza cases and controls using a multivariable logistic regression model and calculated odds ratios adjusted for relevant confounders. Influenza vaccine effectiveness (%) was estimated as $(1 - \text{aOR}) \times 100$,^{11,12} where aOR was the adjusted odds ratio for influenza vaccination from the final regression model.

Planned sensitivity analyses included the following: (1) inclusion of vaccination status based on self-report to assess the statistical effect of exposure misclassification; (2) exclusion of the first influenza season (2009-2010), because our study only included part of this season; (3) redefining the influenza seasons to periods with either at least 4% or 5% of tested samples detected as positive per week in surveillance systems, to evaluate the sensitivity of our estimates to the influenza season definition; (4) restriction to cases and controls hospitalized within 7 and 14 days of symptom onset, to address concerns that influenza may be a concurrent infection and not the cause of pneumonia in patients with longer duration of symptoms prior to presentation^{19,20}; (5) restriction to patients with radiologic evidence of alveolar consolidation, infiltrate, or pleural effusion, as determined by independent study radiologists, a common end point in pneumonia studies²³; (6) considering patients who tested negative for influenza but positive for other noninfluenza viruses (including coronaviruses 229E, HKU1, NL63, and OC43; human metapneumovirus; human rhinovirus; parainfluenza viruses 1, 2, and 3; and respiratory syncytial virus) and those patients who tested negative for all study viruses as alternate controls, to assess the hypothesis that influenza vaccination may increase the risk of noninfluenza viral infections,^{24,25} including pneumonia, and to assess potential differential detection of respiratory viruses^{19,20,25-27}; (7) exclusion of patients who reported use of influenza antivirals prior to admission, as such use may interfere with RT-PCR detection of influenza infections²⁸; (8) reanalyzing our data adjusting for propensity scores^{3,8}

created using variables from the main analysis and 16 additional variables for specific comorbidities, to address concerns about residual confounding; and (9) using respiratory syncytial virus-associated pneumonia as cases and excluding all influenza cases, to assess the specificity of the main findings.

Subgroup analyses included estimations by age group, presence of immunosuppressive and chronic conditions, study site, and influenza season. For these subgroups analyses, interaction terms between subgroup and vaccination status were examined. Estimates for each subgroup were calculated using linear combinations of coefficients from the regression models that included the interaction terms. Separate exploratory analyses for influenza type/subtype and influenza cases with and without co-detection of other pathogens^{16,17} were also conducted.

All reported tests were 2-sided, and a *P* value less than .05 was considered significant. Statistical analyses were conducted in Stata version 13.1 and R version 3.0.2.

Results

Forty-six percent of patients enrolled in the EPIC study (2342/5109) were excluded for the following reasons: age younger than 6 months ($n = 342$, 7%), enrollment outside of the influenza season (714, 14%), children with partial vaccination (300, 6%), vaccination within 14 days of disease onset (115, 2%), self-reported vaccination (518, 10%), self-reported vaccination with unknown vaccination date (52, 1%), unknown vaccination status (210, 4%), and unknown influenza infection status (91, 2%). After exclusions, 2767 patients were included in this study (Figure).


One hundred sixty-two of 2767 patients with pneumonia tested positive for influenza (5.9%) by RT-PCR and were defined as cases, including 62 (38%) with A(H1N1)pdm09, 51 (31%) with A(H3N2), 43 (27%) with influenza B, 4 with influenza A with no available subtype information (3%), and 2 coinfections with influenza A and B (1%). Among 162 influenza cases, 116 cases had only influenza viruses detected, 32 had a viral co-detection, and 14 had a bacterial co-detection. A total of 2605 controls were identified for comparison, including 1196 control patients who tested positive for other respiratory viruses and 1409 control patients who tested negative for all viruses tested.

Characteristics of Cases and Controls

Compared with influenza-negative control patients, influenza-positive case patients had similar age distribution but were more likely to be black and enrolled during the 2010-2011 influenza season. The distribution of influenza cases differed by study site. The prevalence of congenital heart disease and heart failure was higher among controls. Relative to cases, controls were admitted earlier during the influenza seasons. The distribution of other sociodemographic factors and comorbidities was generally similar in both groups (Table 1 and Table 2). There were 2 (1%) in-hospital deaths among case patients and 29 (1%) among control patients.

Confidential. Do not distribute. Pre-embargo material.

Figure. Patient Flowchart in Study of Influenza Vaccination and Influenza Pneumonia



Research sites B and D enrolled only children, site A enrolled only adults, and site C enrolled both children and adults.

^a Influenza infection status could not be determined for 91 patients (1.8% of total enrolled), including patients without samples available for testing and

patients with samples collected after 72 hours of admission or with missing data on the time of sample collection.

^b Noninfluenza respiratory viruses.

Characteristics of Vaccinated and Unvaccinated Patients With Pneumonia

A total of 794 patients (29%) with pneumonia were vaccinated during current influenza seasons. Compared with unvaccinated patients, vaccinated patients were older and more likely to be white and enrolled during the 2010-2011 influenza season. The prevalence of influenza vaccination differed by study research site. The prevalence of current smoking was lower among vaccinated patients, although they were more likely to be past smokers and require home oxygen supplementation. The prevalence of chronic obstructive pulmonary disease, cardiovascular diseases, diabetes, and other chronic medical conditions was generally higher among vaccinated than unvaccinated patients. Unvaccinated patients were admitted earlier than vaccinated patients during the respective influenza seasons (Table 1 and Table 2). There were 11 (1%) in-hospital deaths among vaccinated patients and 20 (1%) among unvaccinated patients. (See eTables 2 and 3 in the Supplement for additional details.)

Association Between Prior Influenza Vaccination and Hospitalization for Influenza-Associated Pneumonia

Of 162 influenza-associated pneumonia cases, 28 (17%) were vaccinated compared with 766 of 2605 (29%) influenza-negative controls. The adjusted odds ratio comparing the odds of prior vaccination among those with influenza-positive pneumonia (cases) with the odds of prior vaccination among those with influenza-negative pneumonia (controls) was 0.43 (95% CI, 0.28-0.68; estimated vaccine effectiveness, 56.7%; 95% CI, 31.9%-72.5%). (See eTable 4 in the Supplement for additional details.)

Results from sensitivity analyses that evaluated key study definitions and assumptions were similar to the main findings. There was no significant association between influenza vaccination and respiratory syncytial virus pneumonia (Table 3).

In subgroup analyses, 7 of 68 case children (10%) were vaccinated compared with 376 of 1309 control children (29%; adjusted odds ratio, 0.25; 95% CI, 0.11-0.58); whereas among adults, 21 of 94 cases (22%) were vaccinated compared with 390 of 1296 controls (30%; adjusted odds ratio, 0.59; 95% CI, 0.34-1.02). Among children aged 0.5 to 4 years, 3 of 40 cases (8%) and 266 of 850 controls (31%) were vaccinated (adjusted odds ratio, 0.16; 95% CI, 0.05-0.53). Among older children and adults, the differences in vaccination between cases and controls were more modest. Among patients without immunosuppression, 13 of 134 cases (10%) were vaccinated compared with 592 of 2212 controls (27%); whereas, among patients with immunosuppression, 15 of 28 cases (54%) were vaccinated compared with 174 of 393 controls (44%). The adjusted odds ratio of prior vaccination between cases and controls was significantly lower among patients without immunosuppression (0.27; 95% CI, 0.14-0.49) compared with patients with immunosuppression (1.22; 95% CI, 0.55-2.71).

The prevalence of prior influenza vaccination was higher among patients with chronic diseases than among those without, and in both groups, vaccination in cases was lower than vaccination in controls (adjusted odds ratio point estimates, 0.54 and 0.24, respectively). Differences in vaccination by site likely reflected the age of the study populations at the sites, and the adjusted odds ratio point estimates ranged from 0.26 to 0.50 across sites. In each of the 2 complete study influenza

Confidential. Do not distribute. Pre-embargo material.

Table 1. Sociodemographic Characteristics of Study Patients by Influenza Infection and Vaccination Status

	Controls: Noninfluenza Pneumonia (n = 2605)	Cases: Influenza Pneumonia (n = 162)	P Value	Nonvaccinated (n = 1973)	Vaccinated (n = 794)	P Value
Children, No. (%)	1309 (50)	68 (42)	.04	994 (50)	383 (48)	.31
Age, median (IQR), y						
Overall	17 (3-55)	31 (5-54)	.18	17 (3-53)	28 (2-65)	<.001
Children	3 (1-6)	3 (1-9)	.23	3 (1-7)	2 (1-6)	.14
Adults	55 (44-68)	52.5 (40-63)	.03	53 (41.5-64)	63 (52-74.5)	<.001
Female sex, No. (%)	1259 (48)	73 (45)	.42	943 (48)	389 (49)	.57
Race/ethnicity, No. (%)						
White	1096 (42)	50 (31)		771 (39)	375 (47)	
Black	1016 (39)	77 (48)	.05	858 (43)	235 (30)	<.001
Hispanic	361 (14)	25 (15)		249 (13)	137 (17)	
Other	132 (5)	10 (6)		95 (5)	47 (6)	
Children aged <5 y at home, No. (%)						
0	563 (22)	38 (23)	.06	432 (22)	169 (21)	.70
≥1	1143 (44)	56 (35)		845 (43)	354 (45)	
Unknown	899 (35)	68 (42)		696 (35)	271 (34)	
Children aged 5-17 y at home, No. (%)						
0	577 (22)	37 (23)	.90	406 (21)	208 (26)	<.001
≥1	1175 (45)	70 (43)		933 (47)	312 (39)	
Unknown	853 (33)	55 (34)		634 (32)	274 (35)	
Research site, No. (%) ^a						
A	717 (28)	63 (39)		587 (30)	193 (24)	
B	544 (21)	38 (23)	.004	497 (25)	85 (11)	<.001
C	1017 (39)	46 (28)		664 (34)	399 (50)	
D	327 (13)	15 (9)		225 (11)	117 (15)	
Influenza season, No. (%)						
2009-2010	305 (12)	6 (4)	.002	266 (13)	45 (6)	<.001
2010-2011	1283 (49)	97 (60)		954 (48)	426 (54)	
2011-2012	1017 (39)	59 (36)		753 (38)	323 (41)	
Insurance, No. (%)						
Public	1396 (54)	91 (56)		1035 (52)	452 (57)	
Private	785 (30)	40 (25)	.01	581 (29)	244 (31)	<.001
Both	176 (7)	5 (3)		104 (5)	77 (10)	
None/other	248 (10)	26 (16)		253 (13)	21 (3)	

Abbreviation: IQR, interquartile range.

^a Research sites B and D enrolled only children, site A enrolled only adults, and site C enrolled both children and adults. Additional information on the

characteristics of the study population is available in eTables 2 and 3 in the Supplement.

seasons, 2010-2011 and 2011-2012, the prevalence of prior vaccination was lower among cases than among controls, and the odds ratio point estimate was 0.44 for both seasons. However, some subgroup analyses had limited precision due to small numbers (Table 4). In separate analyses that evaluated influenza pneumonia cases with and without co-pathogen detections, the odds ratio of vaccination between cases and controls was 0.43 (95% CI, 0.25-0.73) and 0.42 (95% CI, 0.18-0.99), respectively.

In separate assessments, the odds ratio of vaccination between cases and controls was 0.40 (95% CI, 0.19-0.87) for influenza A(H1N1)pdm09, 0.55 (95% CI, 0.28-1.09) for influenza A(H3N2), and 0.28 (95% CI, 0.09-0.83) for influenza B (Table 4).

Discussion

In this study of influenza vaccination status and influenza pneumonia, the findings indicate that the odds of influenza vaccination among cases hospitalized with influenza-associated pneumonia was lower than among noninfluenza pneumonia controls, with an adjusted odds ratio of 0.43 (95% CI, 0.28-0.68; estimated vaccine effectiveness, 56.7%) during the 2009-2012 influenza seasons. This multicenter study addressed several concerns identified in previous influenza vaccine effectiveness assessments. By performing systematic influenza testing for all patients with pneumonia, the study relied on an unbiased sample of laboratory-confirmed

Confidential. Do not distribute. Pre-embargo material.

Table 2. Clinical Characteristics of Study Patients by Influenza Infection and Vaccination Status

	Controls: Noninfluenza Pneumonia (n = 2605)	Cases: Influenza Pneumonia (n = 162)	P Value	Nonvaccinated (n = 1973)	Vaccinated (n = 794)	P Value
Used oxygen supplementation at home, No. (%)	190 (7)	10 (6)	.59	96 (5)	104 (13)	<.001
Adult BMI, median (IQR) ^a	27.4 (23.0-33.0)	27.9 (25.1-34.7)	.08	27.4 (23.1-32.9)	27.7 (23.0-33.4)	.76
Children BMI categories, No. (%) ^b						
Underweight	149 (20)	8 (20)		115 (19)	42 (20)	
Normal	419 (55)	22 (54)	>.99	324 (55)	117 (56)	.84
Overweight	85 (11)	5 (12)		65 (11)	25 (12)	
Obese	108 (14)	6 (15)		88 (15)	26 (12)	
Smoking, No. (%)						
None	1674 (64)	89 (55)		1261 (64)	502 (63)	
Current	374 (14)	38 (23)	.004	327 (17)	85 (11)	<.001
Past	458 (18)	25 (15)		300 (15)	183 (23)	
Unknown	99 (4)	10 (6)		85 (4)	24 (3)	
Chronic conditions ^c	1628 (62)	91 (56)	.11	1159 (59)	560 (71)	<.001
Asthma or reactive airway disease	852 (33)	53 (33)	>.99	635 (32)	270 (34)	.36
Chronic obstructive pulmonary disease	292 (11)	18 (11)	.97	170 (9)	140 (18)	<.001
Congenital heart disease	87 (3)	0	.02	51 (3)	36 (5)	.008
Coronary artery disease	358 (14)	24 (15)	.70	211 (11)	171 (22)	<.001
Heart failure	279 (11)	8 (5)	.02	145 (7)	142 (18)	<.001
Diabetes mellitus	337 (13)	19 (12)	.66	227 (12)	129 (16)	<.001
Blood disorder (eg, sickle cell disease)	189 (7)	8 (5)	.27	120 (6)	77 (10)	<.001
Chronic kidney disease	221 (8)	9 (6)	.19	125 (6)	105 (13)	<.001
Chronic liver disease	82 (3)	9 (6)	.10	60 (3)	31 (4)	.25
Splenectomy	31 (1)	0	.16	16 (1)	15 (2)	.02
Noncancer immunosuppressive condition	223 (9)	17 (10)	.40	134 (7)	106 (13)	<.001
HIV	43 (2)	6 (4)	.06	25 (1)	24 (3)	.002
Cancer	230 (9)	13 (8)	.73	131 (7)	112 (14)	<.001
Immunosuppression ^d	393 (15)	28 (17)	.45	232 (12)	189 (24)	<.001
Seizure disorder	137 (5)	10 (6)	.62	95 (5)	52 (7)	.07
Obstructive sleep apnea	86 (3)	3 (2)	.31	45 (2)	44 (6)	<.001
Cerebral palsy	35 (1)	3 (2)	.59	22 (1)	16 (2)	.07
Dementia	24 (1)	1 (1)	.69	14 (1)	11 (1)	.09
Stroke	72 (3)	2 (1)	.24	45 (2)	29 (4)	.04
Guillain-Barre syndrome	4 (0)	1 (1)	.18	2 (0)	3 (0)	.12
Scoliosis	14 (1)	1 (1)	.89	10 (1)	5 (1)	.69
Down syndrome	38 (1)	0	.12	18 (1)	20 (3)	.001
Other chromosomal abnormality	36 (1)	2 (1)	.88	23 (1)	15 (2)	.14
Currently taking steroids	289 (11)	18 (11)	>.99	192 (10)	115 (14)	<.001
Verified influenza vaccination, No. (%)	766 (29)	28 (17)	<.001	0	(100)	
Influenza confirmed by RT-PCR, No. (%)	0	(100)		134 (7)	28 (4)	<.001
Disease onset to admission, median (IQR), d	3 (2-7)	3 (2-6)	.78	3 (2-7)	3 (2-6)	.51
Admission in flu season, median (IQR), wk	20.0 (13.0-31.0)	26.0 (18.0-32.8)	<.001	18 (11-29)	27 (19-35)	<.001
Vaccination to admission, median (IQR), d	108.5 (64.0-163.0)	124.0 (90.2-150.2)	.52		109.5 (64.2-162.8)	
Season start to admission, median (IQR), d	138 (84-214)	180 (124-224)	<.001	124 (76-198)	184 (127-240)	<.001

Abbreviations: BMI, body mass index; IQR, interquartile range; RT-PCR, reverse-transcription polymerase chain reaction.

^a Calculated as weight in kilograms divided by height in meters squared.

^b Determined per Centers for Disease Control and Prevention guidelines: underweight, <5th percentile of BMI for age; normal, 5th-85th percentile; overweight, 85th-95th percentile; and obese, ≥95th percentile. Additional information on the characteristics of the study population is available in eTables 2 and 3 in the Supplement.

^c Medical conditions associated with influenza-associated complications, including cardiopulmonary disease, diabetes mellitus, blood disorders, chronic liver/kidney disease, immunosuppressive conditions (including cancer), and neuromuscular diseases.

^d Immunosuppression included noncancer immunosuppressive conditions, cancer (other than skin cancer), and HIV infection with CD4 count ≥200/mm³.

Confidential. Do not distribute. Pre-embargo material.

Table 3. Sensitivity Analyses Within Study of Influenza Vaccination and Influenza Pneumonia

	Cases Who Were Vaccinated, No./Total No. (%)	Controls Who Were Vaccinated, No./Total No. (%)	Adjusted Odds Ratio (95% CI)	Estimated Vaccine Effectiveness, % (95% CI) ^a
Overall estimate	28/162 (17)	766/2605 (29)	0.43 (0.28 to 0.68)	56.7 (31.9 to 72.5)
Included self-reported vaccination	56/190 (29)	1241/3270 (38)	0.52 (0.37 to 0.75)	47.5 (25.3 to 63.2)
Influenza season definition				
≥4% Positive tests per week	28/154 (18)	579/1563 (37)	0.41 (0.26 to 0.65)	59.1 (35.3 to 74.1)
≥5% Positive tests per week	28/153 (18)	523/1458 (36)	0.40 (0.25 to 0.63)	60.1 (36.8 to 74.8)
2010-2012 Season	28/156 (18)	721/2300 (31)	0.44 (0.28 to 0.69)	56.4 (31.2 to 72.3)
Hospitalization within 7 d of symptoms onset	23/136 (17)	624/2071 (30)	0.41 (0.25 to 0.68)	58.9 (32.3 to 75.0)
Hospitalization within 14 d of symptoms onset	26/154 (17)	710/2379 (30)	0.43 (0.27 to 0.68)	57.3 (31.7 to 73.2)
Independent radiographic confirmation ^b	24/139 (17)	700/2389 (29)	0.43 (0.27 to 0.71)	56.6 (29.2 to 73.4)
Controls positive for other viruses ^c	28/162 (17)	368/1196 (31)	0.37 (0.23 to 0.61)	62.8 (39.5 to 77.1)
Controls negative for all viruses ^d	28/162 (17)	398/1409 (28)	0.46 (0.29 to 0.74)	53.8 (25.5 to 71.4)
Excluded patients with previous antiviral use	27/155 (17)	750/2546 (29)	0.44 (0.28 to 0.70)	56.2 (30.4 to 72.4)
Propensity score-adjusted analysis ^e	28/162 (17)	766/2605 (29)	0.45 (0.29 to 0.72)	54.9 (28.5 to 71.5)
Cases with respiratory syncytial virus pneumonia ^f	125/396 (32)	641/2209 (29)	1.18 (0.88 to 1.58) ^g	-18.0 (-57.6 to 11.7)

^a Vaccine effectiveness was estimated as $(1 - \text{adjusted odds ratio}) \times 100$, where odds ratio compared the odds of vaccination between cases and controls while controlling for age, sex, race/ethnicity, presence of children at home, smoking status, insurance status, use of oxygen supplementation at home, timing of admission relative to disease onset, timing from beginning of the influenza season to admission, specific influenza season, and presence of immunosuppressive conditions and other chronic medical conditions associated with influenza-associated complications, including cardiopulmonary disease, diabetes mellitus, chronic liver/kidney disease, and neurological disease.

^b Independent radiologic assessment indicated consolidation, infiltrate, or pleural effusion.

^c Control pneumonia patients defined as those who were influenza negative but tested positive for other respiratory viruses.

^d Control pneumonia patients defined as those who tested negative for all respiratory viruses.

^e Propensity score-adjusted analysis included 16 additional variables for individual chronic medical conditions.

^f Evaluated association between influenza vaccination and respiratory syncytial virus pneumonia.

^g Although this odds ratio was not statistically different from 1, the point estimate odds ratio greater than 1 (and the corresponding negative vaccine effectiveness point estimate) indicates that the odds of vaccination among cases was numerically higher than the odds of vaccination among controls.

influenza-pneumonia hospitalizations. Patients with pneumonia were prospectively identified, minimizing concerns about outcome misclassification. To ensure a proper evaluation of the association between influenza pneumonia risk and prior influenza vaccination, the study was restricted to influenza seasons and to patients with similar propensity to require hospital care. Furthermore, vaccination information was actively collected, and only patients with pneumonia and verified influenza vaccination history were included in the main analysis.

Previous studies that used a similar design have shown that influenza vaccination is effective in preventing hospitalizations for acute respiratory illnesses associated with laboratory-confirmed influenza.^{3,7-14} Although some studies had limited precision, the point estimates of effectiveness ranged from 53% to 67% among children,^{10,11} from 54% to 71% among all adults,^{3,12} and from 42% to 61% among adults 65 years or older.^{8,13} However, few studies have examined the effectiveness of influenza vaccination in preventing complications of influenza infections, such as pneumonia. In a recent multinational randomized clinical trial of a new quadrivalent inactivated influenza vaccine in children aged 3 to 8 years, a post hoc analysis of influenza-associated lower respiratory tract illness alone yielded a vaccine efficacy estimate of approximately 80%.²⁹ Likewise, a recent case-control study estimated that influenza vaccination was associated with a 74%

reduction in the odds of pediatric intensive care unit admission during the 2010-2012 seasons.³⁰

Although previous studies focusing on the prevention of all-cause pneumonia have suggested a modest effectiveness of influenza vaccines,^{15,31} using all-cause pneumonia as the outcome for influenza vaccine effectiveness assessments is problematic because influenza is responsible for only a fraction of all pneumonias and varies seasonally, resulting in an underestimation of the true vaccine effectiveness.^{6,19,20,32} The current study avoided this misclassification by applying a prospective and systematic approach for confirming influenza infections and a standardized definition of hospitalizations for pneumonia. The estimated odds ratio of vaccination between cases and controls, and derived vaccine effectiveness from this study, could be used to inform subsequent estimations of the national number of hospitalizations for pneumonia averted by influenza vaccination.³³

Findings from subgroup analyses suggest that the odds ratio of prior influenza vaccination between cases and controls was higher in patients with immunosuppressive conditions, including cancers and HIV infection, suggesting lower vaccine effectiveness. Although several studies have described reduced immunogenicity of influenza vaccines in patients with immunosuppressive conditions, few have evaluated the vaccine effectiveness in preventing influenza pneumonia among

Confidential. Do not distribute. Pre-embargo material.

Table 4. Subgroup Analyses Within Study of Influenza Vaccination and Influenza Pneumonia

Subgroups	Cases Who Were Vaccinated, No./Total No. (%)	Controls Who Were Vaccinated, No./Total No. (%)	Adjusted Odds Ratio (95% CI)	Estimated Vaccine Effectiveness, % (95% CI) ^a	P Value for Interaction ^b
Overall estimate	28/162 (17)	766/2605 (29)	0.43 (0.28 to 0.68)	56.7 (31.9 to 72.5)	
Groups					
Children	7/68 (10)	376/1309 (29)	0.25 (0.11 to 0.58)	74.6 (42.5 to 88.8)	.10
Adults	21/94 (22)	390/1296 (30)	0.59 (0.34 to 1.02)	41.5 (-2.2 to 66.5)	
Age groups, y					
0.5-4	3/40 (8)	266/850 (31)	0.16 (0.05 to 0.53)	84.3 (47.3 to 95.3)	
5-17	4/28 (14)	110/459 (24)	0.48 (0.16 to 1.44)	52.4 (-43.5 to 84.2)	.41
18-49	4/36 (11)	76/433 (18)	0.57 (0.19 to 1.73)	43.1 (-72.5 to 81.2)	
50-64	9/38 (24)	122/354 (34)	0.66 (0.29 to 1.50)	33.9 (-49.7 to 70.8)	
≥65	8/20 (40)	192/409 (47)	0.52 (0.20 to 1.33)	48.4 (-33.3 to 80)	
Immunosuppression					
No	13/134 (10)	592/2212 (27)	0.27 (0.14 to 0.49)	73.4 (51.1 to 85.5)	.003
Yes	15/28 (54)	174/393 (44)	1.22 (0.55 to 2.71) ^c	-21.9 (-170.7 to 45.1)	
Chronic disease					
No	5/71 (7)	229/977 (23)	0.24 (0.09 to 0.62)	75.7 (37.6 to 90.6)	.14
Yes	23/91 (25)	537/1628 (33)	0.54 (0.32 to 0.91)	45.9 (8.6 to 67.9)	
Research site					
A ^d	11/63 (17)	182/717 (25)	0.49 (0.24 to 1.02)	51.1 (-1.56 to 76.41)	
B ^e	2/38 (5)	83/544 (15)	0.26 (0.06 to 1.10)	74.2 (-10.5 to 94)	.83
C	12/46 (26)	387/1017 (38)	0.50 (0.25 to 0.99)	50.5 (1.1 to 75.3)	
D ^e	3/15 (20)	114/327 (35)	0.33 (0.09 to 1.21)	67.2 (-20.8 to 91.1)	
Influenza season ^f					
2010-2011	18/97 (19)	408/1283 (32)	0.44 (0.25 to 0.77)	55.9 (22.5 to 74.8)	.98
2011-2012	10/59 (17)	313/1017 (31)	0.44 (0.22 to 0.90)	55.9 (9.8 to 78.4)	
Virus type/subtype ^g					
A(H1N1)pdm09	9/62 (15)	766/2605 (29)	0.40 (0.19 to 0.87)	59.5 (13.0 to 81.2)	
A(H3N2)	14/51 (27)	766/2605 (29)	0.55 (0.28 to 1.09)	45.1 (-9.3 to 72.4)	
B	4/43 (9)	766/2605 (29)	0.28 (0.09 to 0.83)	72.0 (16.8 to 90.6)	

^a Vaccine effectiveness was estimated as $(1 - \text{adjusted odds ratio}) \times 100$, where odds ratio compared the odds of vaccination between cases and controls while controlling for age, sex, race/ethnicity, presence of children at home, smoking status, insurance status, use of oxygen supplementation at home, timing of admission relative to disease onset, timing from beginning of the influenza season to admission, specific influenza season, and presence of immunosuppressive conditions and other chronic medical conditions associated with influenza-associated complications, including cardiopulmonary disease, diabetes mellitus, chronic liver/kidney disease, and neurological disease.

^b Reported P values correspond to the interaction term between subgroup and vaccination status. Subgroup estimates were calculated using linear combinations of coefficients from the regression models that included the interaction terms.

^c Although this odds ratio was not statistically different from 1, the point estimate odds ratio greater than 1 (and the corresponding negative vaccine effectiveness point estimate) indicates that the odds of vaccination among cases was numerically higher than the odds of vaccination among controls.

^d Adult-only site.

^e Children-only site.

^f Estimates for 2009-2010 season could not be calculated separately because there were no vaccinated participants among the influenza cases.

^g Separate estimates were conducted for influenza virus type/subtype.

such patients. A small, open-label randomized clinical trial of influenza vaccination among patients with multiple myeloma reported a nonsignificant reduction in all-cause pneumonia, but the number of events was small and the study included only 1 season.³⁴ Other observational influenza vaccine effectiveness studies have reported reductions in all-cause pneumonia in patients with immunosuppressive conditions, but these events were not confirmed influenza infections.³⁵ Evidence for the effectiveness of influenza vaccines in preventing pneumonia among patients with HIV infection is also limited.³⁶ Although these findings warrant replication in other

settings, they highlight the vulnerability of older adults and patients with immunosuppressive conditions and the need for additional measures to reduce their risk of influenza infection and related complications.

One concern with observational studies of influenza-associated hospitalizations is the control of unmeasured or poorly measured confounding factors, such as disease severity or baseline characteristics that increase the likelihood that pneumonia will require hospitalization. For example, retrospective studies of influenza vaccination and all-cause mortality have reported that indicators of poor functional status

Confidential. Do not distribute. Pre-embargo material.

are relevant confounders, because they are associated with both likelihood of not being vaccinated and risk of death, but are rarely considered.³⁷ The current study used a test-positive case, test-negative control design, a design widely used for vaccine effectiveness assessments that has been shown to be superior to case-control studies of hospitalized cases with population controls, because the likelihood of hospitalization is implicitly accounted for.^{19,20} In addition, the current study excluded nursing home residents with limited functional status and prospectively gathered information on risk factors for pneumonia.^{19,38,39}

The study findings must be interpreted in light of several limitations. First, although an extensive evaluation of potential threats to the validity of the estimates was conducted, the observational design is vulnerable to some misclassification and residual confounding. Nevertheless, the use of a well-established design and the consistency of findings in a number of prespecified sensitivity analyses conducted to evaluate key assumptions should help reduce these concerns. Second, despite enrollment over 3 consecutive seasons, a relatively small number of influenza-associated pneumonia cases met eligibility criteria, resulting in limited precision for some subgroup analyses. Thus, the association between influenza vaccines and pneumonia among older adults remains controversial, and additional studies in this group are needed.^{2,5,7} Although different types of vaccines are available and some ecological evidence suggests that influenza A(H3N2) strains are associated with higher pneumonia mortality,⁴⁰ more detailed assessments by vaccine type, specific influenza types/subtypes, or history of previous vaccination were not possible.

Third, patients missing verified vaccination status were excluded from the main analysis. However, a sensitivity analysis showed that including patients with unverified but self-reported vaccination information likely introduced misclassification and diluted the observed association. If influenza case patients who were excluded because of unknown vaccination were indeed not vaccinated, then the findings could have overestimated the true odds ratios (and underestimated the vaccine effectiveness). Fourth, although the study comprised a diverse population, it included only 4 US geographical areas, which may prevent direct extrapolation of the findings to other settings. Fifth, the study included only a few influenza seasons during which vaccine strains were generally well matched with the circulating influenza strains.⁴⁰ Sixth, it is possible that some pneumonia cases were secondary to an earlier influenza infection that could have been missed by the tests. However, this concern is most likely not of substantial importance because the median time from disease onset to hospitalization was only 3 days. Furthermore, the study focused on pneumonia hospitalizations only, and additional studies in the ambulatory setting would be useful to complement these findings.^{2,7}

Conclusions

Among children and adults hospitalized with community-acquired pneumonia, those with laboratory-confirmed influenza-associated pneumonia, compared with those with pneumonia not associated with influenza, had lower odds of having received influenza vaccination.

ARTICLE INFORMATION

Published Online: October 5, 2015.
doi:10.1001/jama.2015.12160.

Author Affiliations: Vanderbilt University School of Medicine, Nashville, Tennessee (Grijalva, Zhu, Williams, Self, Griffin, Edwards); Geriatric Research Education Clinical Center (GRECC), VA Tennessee Valley, Nashville (Grijalva, Griffin); University of Utah School of Medicine, Salt Lake City (Ampofo, Pavia, Stockmann); University of Tennessee School of Medicine, Memphis (McCullers, Arnold); Northwestern University School of Medicine, Chicago, Illinois (Wunderink); Emory University School of Medicine, Atlanta, Georgia (Anderson); Centers for Disease Control and Prevention, Atlanta, Georgia (Lindstrom, Fry, Foppa, Finelli, Bramley, Jain); Battelle Memorial Institute, Atlanta, Georgia (Foppa).

Author Contributions: Drs Grijalva and Zhu had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Grijalva, Williams, Ampofo, Pavia, Stockmann, McCullers, Arnold, Anderson, Finelli, Jain, Edwards.

Acquisition, analysis, or interpretation of data: Grijalva, Zhu, Williams, Self, Pavia, Stockmann, Arnold, Wunderink, Anderson, Lindstrom, Fry, Foppa, Finelli, Bramley, Jain, Griffin, Edwards.

Drafting of the manuscript: Grijalva, Ampofo, Stockmann, Anderson, Finelli, Jain.

Critical revision of the manuscript for important intellectual content: Grijalva, Zhu, Williams, Self, Pavia, Stockmann, McCullers, Arnold, Wunderink, Anderson, Lindstrom, Fry, Foppa, Finelli, Bramley, Jain, Griffin, Edwards.

Statistical analysis: Grijalva, Zhu, Williams, Stockmann, Finelli.

Obtained funding: Grijalva, Williams, Wunderink, Jain, Edwards.

Administrative, technical, or material support: Williams, Self, Ampofo, Stockmann, Wunderink, Lindstrom, Foppa, Bramley, Jain, Edwards.

Study supervision: Grijalva, Self, Stockmann, Finelli, Jain, Edwards.

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Grijalva reported having served as a consultant with Pfizer. Dr Self reported having received grants from bioMerieux, Affinium Pharmaceuticals, Astute Medical, Crucell Holland, BRAHMS, Pfizer, Rapid Pathogen Screening, Venaxis, and Cembra Pharmaceuticals and other support from CareFusion and BioFire Diagnostics and having a patent pending 13/632,874 (Sterile Blood Culture Collection System). Dr Ampofo reported having received grants from the National Institutes of Health and other support from GlaxoSmithKline and Cubist Pharmaceuticals and having collaborated with BioFire Diagnostics. Dr Pavia reported having received grants from Pfizer and the Agency for Healthcare Research and Quality and

other support from BioFire Diagnostics, Medscape, and Antimicrobial Therapy. Dr Stockmann reported having received grants from the American Foundation for Pharmaceutical Education. Dr Arnold reported having received grants from GlaxoSmithKline. Dr Wunderink reported having participated on a data and safety monitoring committee for Vertex and having received other support from Visterra, bioMerieux, and Roche. Dr Anderson reported having received grants and other support from MedImmune, Roche, and AbbVie. Dr Griffin reported having received grants from MedImmune. Dr Edwards reported having received grants from the National Institutes of Health and Novartis and having participated on data monitoring boards for the University of Maryland and Novartis. No other disclosures were reported.

Funding/Support: This study was funded by the Influenza Division in the National Center for Immunization and Respiratory Diseases at the Centers for Disease Control and Prevention (CDC).

Role of the Funders/Sponsors: Investigators from CDC, the study sponsor, participated in the conduct of the study; collection, management, and interpretation of the data; preparation, review, and approval of the manuscript. The sponsors did not perform any of the study analyses.

Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the

Confidential. Do not distribute. Pre-embargo material.

Centers for Disease Control and Prevention or the Department of Veterans Affairs.

Previous Presentation: An abstract of part of this work was presented at the IDWeek Annual meeting; October 2-6, 2013; San Francisco, California.

REFERENCES

- Fiore AE, Uyeki TM, Broder K, et al; Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. *MMWR Recomm Rep*. 2010;59(RR-8):1-62.
- Grohskopf LA, Olsen SJ, Sokolow LZ, et al; Centers for Disease Control and Prevention. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP): United States, 2014-15 influenza season. *MMWR Morb Mortal Wkly Rep*. 2014;63(32):691-697.
- Talbot HK, Zhu Y, Chen Q, Williams JV, Thompson MG, Griffin MR. Effectiveness of influenza vaccine for preventing laboratory-confirmed influenza hospitalizations in adults, 2011-2012 influenza season. *Clin Infect Dis*. 2013;56(12):1774-1777.
- Belshe RB, Edwards KM, Vesikari T, et al; CAIV-T Comparative Efficacy Study Group. Live attenuated versus inactivated influenza vaccine in infants and young children. *N Engl J Med*. 2007;356(7):685-696.
- Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. *Lancet Infect Dis*. 2012;12(1):36-44.
- Belongia EA, Shay DK. Influenza vaccine for community-acquired pneumonia. *Lancet*. 2008;372(9636):352-354.
- Griffin MR. Influenza vaccination: a 21st century dilemma. *S D Med*. 2013;(Spec no):110-118.
- Talbot HK, Griffin MR, Chen Q, Zhu Y, Williams JV, Edwards KM. Effectiveness of seasonal vaccine in preventing confirmed influenza-associated hospitalizations in community dwelling older adults. *J Infect Dis*. 2011;203(4):500-508.
- Treanor JJ, Talbot HK, Ohmit SE, et al; US Flu-VE Network. Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains. *Clin Infect Dis*. 2012;55(7):951-959.
- Staat MA, Griffin MR, Donauer S, et al. Vaccine effectiveness for laboratory-confirmed influenza in children 6-59 months of age, 2005-2007. *Vaccine*. 2011;29(48):9005-9011.
- Menniti-Ippolito F, Da Cas R, Traversa G, et al; Italian Multicentre Study Group for Drug and Vaccine Safety in Children. Vaccine effectiveness against severe laboratory-confirmed influenza in children: results of two consecutive seasons in Italy. *Vaccine*. 2014;32(35):4466-4470.
- Puig-Barberà J, Díez-Domingo J, Arnedo-Pena A, et al. Effectiveness of the 2010-2011 seasonal influenza vaccine in preventing confirmed influenza hospitalizations in adults: a case-case comparison, case-control study. *Vaccine*. 2012;30(39):5714-5720.
- Kwong JC, Campitelli MA, Gubbay JB, et al. Vaccine effectiveness against laboratory-confirmed influenza hospitalizations among elderly adults during the 2010-2011 season. *Clin Infect Dis*. 2013;57(6):820-827.
- Castilla J, Godoy P, Domínguez A, et al; CIBERESP Cases and Controls in Influenza Working Group Spain. Influenza vaccine effectiveness in preventing outpatient, inpatient, and severe cases of laboratory-confirmed influenza. *Clin Infect Dis*. 2013;57(2):167-175.
- Ferdinands JM, Gargiullo P, Haber M, Moore M, Belongia EA, Shay DK. Inactivated influenza vaccines for prevention of community-acquired pneumonia: the limits of using nonspecific outcomes in vaccine effectiveness studies. *Epidemiology*. 2013;24(4):530-537.
- Jain S, Williams DJ, Arnold SR, et al; CDC EPIC Study Team. Community-acquired pneumonia requiring hospitalization among US children. *N Engl J Med*. 2015;372(9):835-845.
- Jain S, Self WH, Wunderink RG, et al; CDC EPIC Study Team. Community-acquired pneumonia requiring hospitalization among US adults. *N Engl J Med*. 2015;373(5):415-427.
- Petrie JG, Ohmit SE, Johnson E, Cross RT, Monto AS. Efficacy studies of influenza vaccines: effect of end points used and characteristics of vaccine failures. *J Infect Dis*. 2011;203(9):1309-1315.
- Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. *Vaccine*. 2013;31(17):2165-2168.
- Foppa IM, Haber M, Ferdinands JM, Shay DK. The case test-negative design for studies of the effectiveness of influenza vaccine. *Vaccine*. 2013;31(30):3104-3109.
- FluView: national and regional level outpatient illness and viral surveillance. Centers for Disease Control and Prevention. <http://gis.cdc.gov/grasp/fluview/fluportal/dashboard.html>. Accessed September 15, 2015.
- Poehling KA, Edwards KM, Weinberg GA, et al; New Vaccine Surveillance Network. The underrecognized burden of influenza in young children. *N Engl J Med*. 2006;355(1):31-40.
- Cherian T, Mulholland EK, Carlin JB, et al. Standardized interpretation of paediatric chest radiographs for the diagnosis of pneumonia in epidemiological studies. *Bull World Health Organ*. 2005;83(5):353-359.
- Cowling BJ, Fang VJ, Nishiura H, et al. Increased risk of noninfluenza respiratory virus infections associated with receipt of inactivated influenza vaccine. *Clin Infect Dis*. 2012;54(12):1778-1783.
- Sundaram ME, McClure DL, VanWormer JJ, Friedrich TC, Meece JK, Belongia EA. Influenza vaccination is not associated with detection of noninfluenza respiratory viruses in seasonal studies of influenza vaccine effectiveness. *Clin Infect Dis*. 2013;57(6):789-793.
- Kelly H, Jacoby P, Dixon GA, et al; WAIVE Study Team. Vaccine effectiveness against laboratory-confirmed influenza in healthy young children: a case-control study. *Pediatr Infect Dis J*. 2011;30(2):107-111.
- Cowling BJ, Nishiura H. Virus interference and estimates of influenza vaccine effectiveness from test-negative studies. *Epidemiology*. 2012;23(6):930-931.
- Fry AM, Goswami D, Nahar K, et al. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial. *Lancet Infect Dis*. 2014;14(2):109-118.
- Jain VK, Rivera L, Zaman K, et al. Vaccine for prevention of mild and moderate-to-severe influenza in children. *N Engl J Med*. 2013;369(26):2481-2491.
- Ferdinands JM, Olsho LE, Agan AA, et al; Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network. Effectiveness of influenza vaccine against life-threatening RT-PCR-confirmed influenza illness in US children, 2010-2012. *J Infect Dis*. 2014;210(5):674-683.
- Jackson ML, Nelson JC, Weiss NS, Neuzil KM, Barlow W, Jackson LA. Influenza vaccination and risk of community-acquired pneumonia in immunocompetent elderly people: a population-based, nested case-control study. *Lancet*. 2008;372(9636):398-405.
- Jackson ML, Yu O, Nelson JC, et al. Further evidence for bias in observational studies of influenza vaccine effectiveness: the 2009 influenza A(H1N1) pandemic. *Am J Epidemiol*. 2013;178(8):1327-1336.
- Kostova D, Reed C, Finelli L, et al. Influenza illness and hospitalizations averted by influenza vaccination in the United States, 2005-2011. *PLoS One*. 2013;8(6):e66312.
- Musto P, Carotenuto M. Vaccination against influenza in multiple myeloma. *Br J Haematol*. 1997;97(2):505-506.
- Eliakim-Raz N, Vinograd I, Zalmanovici Trestioreanu A, Leibovici L, Paul M. Influenza vaccines in immunosuppressed adults with cancer. *Cochrane Database Syst Rev*. 2013;10:CD008983.
- Beck CR, McKenzie BC, Hashim AB, et al. Influenza vaccination for immunocompromised patients: summary of a systematic review and meta-analysis. *Influenza Other Respir Viruses*. 2013;7(suppl 2):72-75.
- Jackson LA, Nelson JC, Benson P, et al. Functional status is a confounder of the association of influenza vaccine and risk of all cause mortality in seniors. *Int J Epidemiol*. 2006;35(2):345-352.
- Fleming DM, Andrews NJ, Ellis JS, et al. Estimating influenza vaccine effectiveness using routinely collected laboratory data. *J Epidemiol Community Health*. 2010;64(12):1062-1067.
- Orenstein EW, De Serres G, Haber MJ, et al. Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness. *Int J Epidemiol*. 2007;36(3):623-631.
- Flu activity and surveillance. Centers for Disease Control and Prevention. <http://www.cdc.gov/flu/weekly/fluactivitysurv.htm>. Accessed June 15, 2015.